NCT07719426Not yet recruiting
Characterization of Colorectal Dysplasic Lesions and Stratification of Their Evolving Risk in Inflammatory Bowel Disease Patients: a Prospective, Observational and Multicenter Study
Source: ClinicalTrials.gov · Last updated 22 Jul 2026
Brief summary (registry, in English)
Inflammatory Bowel Disease (IBD) patients have an increased risk of ColoRectal Cancer (CRC). The cumulative risk of CRC development is estimated at 1% after 10 years of disease progression, 2% after 20 years, and 5% after more than 20 years of disease progression (1). The incidence of CRC in IBD has gradually declined, attributed to enhanced detection of preneoplastic lesions (dysplasia), improved adherence to screening recommendations, utilization of advanced high-definition endoscopes (2-4), and the implementation of more efficacious therapeutic strategies (5-9). Presently, there is no consensus on the endoscopic management of dysplastic lesions. Recent techniques such as submucosal dissection (ESD) enable the resection of non-polypoid flat lesions larger than 2 cm. Lesions previously treated with colectomy can now be resected by ESD with en-bloc resection rates of approximately 85.7% (17). However, long-term data on the risk of local or distant recurrence after endoscopic resection in IBD is lacking. It is crucial to evaluate complete (R0) and curative resection rates, as well as the rate of local recurrence, based on the type of endoscopic treatment. In light of the 21st century advancements, characterized by high-definition endoscopes and targeted treatments, it is imperative to: * Assess the prevalence and incidence of dysplasia in IBD and its risk of progression to CRC. * Specifically characterize the endoscopy and histology of pre-neoplastic lesions in IBD to facilitate better selection of lesions amenable to endoscopic treatment or surgery. * Evaluate the rates of local and distant recurrence over time, considering factors associated with this evolving risk (IBD characteristics, endoscopic appearance, histology, type of resection, etc.).
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 800 (estimated)
- First submitted
- 17 Jul 2026
- Start date
- 15 Sept 2026
- Primary completion date
- 15 Sept 2033
- Lead sponsor
- Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives
- Diseases
- Crohn's disease, Ulcerative colitis
- NCT number
- NCT07719426
What you commit to
- Study type: Observational
- Planned participants: 800
- From 15 Sept 2026 to the primary completion date, 15 Sept 2033
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patient referred for a therapeutic endoscopic procedure, without prior or subsequent follow-up in the participating center
Other illness
- Patient followed for ileal Crohn's disease (L1)
Age
- Patients \< 18 years old
Other
- Patient followed for rectal ulcerative colitis (E1)
- Patient under guardianship or curatorship
- Patient objects to their personal data being used in the context of research
Who the study is looking for
- Patients age ≥ 18 years
- Documented diagnosis of CD or UC established based on standard clinical, endoscopic and histological criteria.
- IBD patients requiring screening colonoscopy for dysplasia as following:
- IBD (CD/UC) evolving for more than 8 years, or for ≥1 year if associated with Primary Sclerosing Cholangitis (PSC)
- For UC: Extended ulcerative colitis (E2 or E3 in the Montreal classification)
- For CD: Colonic (L2) or ileocolonic (L3) Crohn's disease with \> 50% involvement of the colon.
- Patient affiliated to the health security system
- Patient who has received information about the study by the investigator and agreed to participate.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.